Menu Search
Equities

Seelos Therapeutics Inc

SEELQ:PKL

Seelos Therapeutics Inc

Actions
  • Price (USD)0.48
  • Today's Change0.061 / 14.56%
  • Shares traded14.02k
  • 1 Year change-99.73%
  • Beta1.7309
Data delayed at least 15 minutes, as of Dec 03 2024 17:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Seelos Therapeutics Inc grew revenues -- from 0.00 to 2.20m while net income improved from a loss of 73.53m to a smaller loss of 37.88m.
Gross margin--
Net profit margin203.13%
Operating margin-1,734.46%
Return on assets57.34%
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at Seelos Therapeutics Inc fell by 12.54m. Cash Flow from Financing totalled 11.38m or 516.34% of revenues. In addition the company used 23.91m for operations while cash used for investing totalled .
Cash flow per share--
Price/Cash flow per share--
Book value per share-135.50
Tangible book value per share-135.50
More ▼

Balance sheet in USDView more

Seelos Therapeutics Inc uses little or no debt in its capital structure.
Current ratio0.0765
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.